智通财经记者 | 周芳颖 智通财经编辑 | 楼婍沁 针对近期网传雪花秀大面积撤柜、即将退出中国市场的传闻，雪花秀母公司爱茉莉太平洋中国向界面时 尚予以否认，并强调"中国始终是雪花秀品牌重要的战略市场"，希望通过"渠道优化与数字化革新"继续 在中国市场发展。 另有雪花秀内部人员则告诉界面时尚，中国市场预计撤柜数量大约为30家，主要集中于二线城市。这与 界面时尚比对官网门店信息及点评平台数据后得到的结果基本一致。以长沙为例，官网显示该城市有4 家雪花秀门店，但实际上目前仅剩一个专柜；而在南宁、苏州等城市，雪花秀已无门店。值得提到的 是，综合财报及官网信息，雪花秀在中国市场的门店数量约为180家。 界面时尚实地走访发现，在一线城市上海，雪花秀的门店规模也有收缩。雪花秀位于上海百盛百货、已 运营14年的门店于近期撤柜。 不过，据界面时尚了解，该个例与雪花秀所选渠道的自身调整关联度更高。雪花秀偏好在传统百货设 柜，而不少百货商场在近年也处于调改周期。上海百盛商场工作人员向界面时尚表示，上海百盛正同步 压缩一楼化妆品区域面积，11月以来已有多个美妆品牌陆续撤出，相关铺位面积后续将替换为服装品 牌。 一增长亦与2024年基 ...

Core Insights - The article highlights the successful introduction of new products by Kao Corporation at the China International Import Expo, showcasing their commitment to local market adaptation and innovation [1][2] Group 1: Product Innovation - Kao introduced a fresh flower preservation solution that significantly extends the lifespan of flowers by inhibiting cell aging and maintaining water flow, addressing common issues like wilting and odor [1] - The company showcased its localized product line, including 23 different color variants of the foam hair dye "Lijie," tailored specifically for Chinese consumers, reflecting a shift from imported to locally produced goods [1] Group 2: Market Strategy - Kao has participated in the Import Expo for eight consecutive years, evolving from primarily showcasing imported products to featuring locally produced innovations [1] - The company plans to continue leveraging the Import Expo as a platform for ongoing local innovation and to better understand Chinese consumer needs, as stated by the chairman of Kao (China) [2]

Core Insights - dōTERRA has launched a new product, the mugwort essential oil, at the China International Import Expo (CIIE), marking a significant expansion of its product line into the edible oil sector through a strategic partnership with Xianle Health [3][6] - The company has experienced substantial growth in China since its first participation in CIIE, evolving from a small 9-square-meter booth to a 300-square-meter presence, reflecting its increasing market acceptance and success [9][10] Product Launch and Innovation - The mugwort essential oil is derived from traditional Chinese herbal practices and is designed to meet the needs of Chinese consumers, showcasing dōTERRA's commitment to local innovation [5][6] - The new product is part of a broader strategy to incorporate traditional Chinese herbs into modern essential oil applications, enhancing the company's product matrix [5][6] Strategic Partnerships - dōTERRA signed a strategic cooperation agreement with Xianle Health, leveraging Xianle's expertise in nutritional health products to develop innovative edible essential oil products [6][11] - The collaboration aims to create functional gummies and oral liquids that combine high-quality essential oils with nutritional benefits, targeting the health-conscious Chinese consumer [6][11] Market Growth and Development - Since its inception in China, dōTERRA has seen a dramatic increase in order volumes, with initial orders from the first CIIE reaching 3.8 billion yuan, and subsequent years showing continued growth in both booth size and order amounts [9][10] - The establishment of a research and development center in Shanghai has allowed dōTERRA to expedite the product development process, enhancing its ability to respond to local market demands [10] Future Outlook - dōTERRA views CIIE as a vital platform for engaging with the Chinese market, emphasizing its role in fostering new ideas and collaborations [11] - The company advocates for the establishment of a small and medium-sized enterprise alliance at CIIE to support other businesses in finding opportunities for growth [11]

Core Insights - The article emphasizes the strategic importance of the Chinese market for multinational companies, particularly for Zeiss, which views China as a key driver of global innovation and supply chain development [1][2] - Zeiss has achieved significant engagement at the China International Import Expo (CIIE), with intentions exceeding 400 million RMB this year [1][8] Company Strategy - Zeiss has been actively increasing its investment in China, focusing on local innovation and expanding its manufacturing and R&D capabilities in the Yangtze River Delta region [4][5] - The company plans to establish a comprehensive headquarters in Shanghai, covering 60 acres with an investment exceeding 600 million RMB, expected to be operational by 2027 [4][5] Market Performance - China has become Zeiss's largest single market globally since 2021, with revenue reaching 15.1 billion RMB in the 2023/24 fiscal year, accounting for nearly 20% of the company's total business [7] - The demand for high-end manufacturing, semiconductors, and life sciences in China continues to grow, providing ample opportunities for Zeiss's products [7] Competitive Landscape - The company acknowledges the increasing competition from local brands and emphasizes the need to participate in the market like a local enterprise, focusing on R&D and innovation speed as key competitive factors [8] - Zeiss has adapted its global distribution strategy to mitigate risks from geopolitical tensions, including localizing more production in China and shifting some manufacturing from the U.S. to Europe [8]

Group 1: Core Insights - The China International Import Expo (CIIE) serves as a platform for understanding the transformation of foreign investment in China, highlighting the shift from merely importing to local production and R&D [1] - Amid global uncertainties, China's commitment to "openness and development" is increasingly evident, making it a key player in global trade [1] Group 2: Global Competitiveness - Companies like Zeiss emphasize the importance of China's complete and responsive supply chain as a critical support for enhancing global competitiveness [2] - Zeiss is dynamically adjusting its global supply chain to minimize tariff impacts, moving parts of its supply chain from the U.S. to Germany and from Germany to China [2][3] - China has become Zeiss's largest market, contributing nearly 20% to the group's revenue, with ongoing discussions about local procurement standards [3] Group 3: Localization and Innovation - Companies are increasingly focusing on localizing their operations in China, with a shift from "local manufacturing" to "local R&D" and "local decision-making" [5] - Adidas has achieved over 60% of its products in China being designed by local teams, leading to significant growth in the Greater China region [8] - The collaboration between Japanese and Chinese teams in companies like Kao Group highlights the importance of local R&D in meeting diverse consumer needs [11] Group 4: Supply Chain Resilience - The establishment of local production bases, such as Schott's facility in Zhejiang, enhances supply security and benefits from China's supply chain advantages [4] - Schott's revenue in China reached approximately 2.42 billion RMB, reflecting a 3% growth after excluding exchange rate factors [10] - The new production line for Schott in Suzhou aims to support the innovation of the Chinese automotive industry, particularly in electric vehicles [10] Group 5: Sustainability and Innovation - SKF's commitment to achieving net-zero emissions by 2030 aligns with China's dual carbon goals, showcasing a commitment to sustainable manufacturing practices [12] - The introduction of SKF's near-zero carbon bearings at the CIIE demonstrates the company's focus on innovative and sustainable solutions [11][12]

Group 1 - The 8th China International Import Expo (CIIE) was held in Shanghai from November 5 to 10, showcasing Marriott International's significant growth in China, with over 660 hotels across more than 150 cities and destinations [1][2] - Marriott International's brand, Four Points by Sheraton, is celebrating its 30th anniversary globally, with nearly 100 hotels set to open in China, reflecting strong demand in the select-service market [1][2] - The company has over 660 hotels and more than 90,000 employees in the Greater China region, serving 260 million members of the "Marriott Bonvoy" loyalty program [2] Group 2 - The World Travel and Tourism Council predicts that by 2035, China's tourism industry will contribute over 27 trillion RMB to the economy, with a growth rate double that of the overall economy [5] - Marriott International is leveraging industry opportunities through local innovations to drive business growth and enhance customer experiences, with a record number of new hotel openings expected by Q3 2025 in the Greater China region [5]

Core Insights - The 8th China International Import Expo (CIIE) highlights the automotive and smart mobility sector, with General Motors (GM) showcasing its commitment to the Chinese market through innovative local models [1][3] - GM's participation for the eighth consecutive year reflects its confidence in the Chinese market and its strategy of deepening local innovation [3][7] Product Innovations - The Buick Zhijing L7, a flagship electric vehicle, represents GM's local innovation efforts, featuring the "Xiaoyao" super integration architecture and the "Zhenlong" range extender system [3][5] - The Baojun Yueye PLUS, a smart electric SUV, appeals to younger consumers with its unique design and versatility for various urban mobility needs, showcasing GM's experience in the Chinese EV market [5][7] Strategic Partnerships - GM's collaboration with SAIC Motor and its joint ventures are central to its competitive edge in China, leveraging local partnerships and global resources for continued innovation [7][8] - The company's strategy aligns with the upgraded focus of the CIIE on smart, electric, and connected vehicles, presenting a comprehensive future mobility solution [7] Financial Performance - In Q3, GM reported a net revenue of $48.6 billion and an adjusted EBIT of $3.4 billion, with an EBIT margin of 6.9%, exceeding market expectations [7] - GM has achieved profitability in the Chinese market for four consecutive quarters, reinforcing its recovery since the business restructuring last year [7][8]

Core Insights - The 8th China International Import Expo will commence on November 5 in Shanghai, with Zeiss participating for the eighth consecutive year, showcasing over 60 innovative solutions across four business areas [1][2] - Zeiss aims to highlight local innovations and unveil new strategic initiatives and collaboration projects during the expo [1] - China has become Zeiss's largest single market globally since 2021, with a workforce of over 7,000 employees across more than 60 production, sales, service, and R&D centers in the region [1][2] Group 1: Investment and Local Development - Zeiss has increased investment in China, focusing on the Yangtze River Delta and Greater Bay Area as development hubs, leveraging local supply chains to create high-end equipment and eye health centers [2] - The comprehensive headquarters project in the Greater China region, set to launch in 2025, will integrate and upgrade existing operations, enhancing efficiency and market responsiveness [2] Group 2: Product Innovations - In September, Zeiss launched three locally manufactured high-end microscopes, including the LSM910 laser confocal microscope, which offers new solutions for life sciences and materials research [2] - The digital navigation surgical microscope ZEISS ARTEVO750 will debut at the expo, featuring a 21% improvement in optical resolution compared to its predecessor [2] - The first domestically produced high-end surgical microscope, PENTERO800S, will also be showcased, designed for neurosurgery and reconstructive surgery [3] - A new vision health product, the Zeiss Diamond Cube Gold Coating, will be presented, enhancing lens purity and cleanliness while offering a unique aesthetic appeal [3]

Core Viewpoint - The article discusses the upcoming 2025 Shanghai Leading Industry Conference, focusing on the themes of innovation in the pharmaceutical sector and the global expansion of Chinese pharmaceutical companies [1][3][30]. Group 1: Event Overview - The 2025 Shanghai Leading Industry Conference will take place on September 4-5, 2025, at the Mandarin Oriental Hotel in Pudong, Shanghai [1]. - The conference will include the 14th Pharmaceutical CEO Forum and the 5th Artificial Intelligence Conference, highlighting the intersection of these two critical sectors [1][30]. Group 2: Industry Trends - The article emphasizes the transition of Chinese pharmaceutical companies from local innovation to global leadership, marking a significant shift in the industry landscape [3][30]. - It suggests that the future of medicine lies in the birth of new blockbuster drugs, with a focus on identifying the next billion-dollar opportunities [9][30]. Group 3: Discussion Themes - Key discussion topics will include the exploration of future disease areas and technological fields that could drive innovation in the pharmaceutical industry [22][30]. - The conference aims to facilitate dialogue on the challenges and breakthroughs in moving from research and development to commercialization [30].